Healthcare Global Enterprises Ltd.
Snapshot View

253.70 +9.65 ▲4.0%

30 July 2021, 04:00:00 P.M.
Volume: 56,732

Overview View Details

Sector Miscellaneous Compare with Sector peers
Industry Miscellaneous Compare with Industry peers
Website http://www.hcgoncology.com
Financial Indicators
Market Cap 3,134.23 Cr.
Earnings per share (EPS) -15.43 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 113.69 Trailing Twelve Months Ending 2021-03
Book Value / Share 55.60 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.50 Calculated using Price: 249.95
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 12.54 Cr. 125,394,284 Shares
FaceValue 10
Company Profile

Healthcare Global Enterprises was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.

The company is a provider of speciality healthcare services in India focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB . Under the “Milann” brand, it operates its fertility centres.

The company’s HCG network operates on a “hub and spoke” model, wherein its HCG centre of excellence in Bengaluru serves as a “hub” to its other cancer centres. Its centre of excellence provides its other centres access to centralised quality control and assurance services; establishes treatment protocols that are adhered to across its HCG network; provides centralised treatment planning and tele-radiology services to help with diagnosis and treatment; conducts weekly central tumour board meetings to review complex cases; and also gives its HCG network access to advanced technologies, such as WBRRS and specialised procedures such as liver transplants and stem cell therapies. This model allows HCG network of cancer centres to leverage the expertise and capabilities of its centre of excellence, which when combined with the diagnostic and treatment facilities at its cancer centres, allows it to deliver quality cancer care to patients across India in a seamless manner.

The company follows a multidisciplinary approach to cancer care across its HCG network, wherein specialist physicians from various disciplines collaborate to provide the best course of treatment for each patient. This allows it to share and develop best practices, build clinical expertise and adopt standardised protocols for diagnosis and treatment, thereby improving the quality of its cancer care services. As a result, the company is able to better serve its patients and ensure consistent clinical outcomes.

Given the large number of patient cases treated across its HCG network, the company is able to efficiently utilise its equipment, technologies and human resources, thereby deriving economies of scale. Furthermore, through the adoption of a centralised drug and consumables formulary, it is able to lower the overall cost of drugs and consumables. Its business model is scalable and when combined with efficient utilisation of resources, it enables it to operate within a competitive cost structure.

Business area of the company

The company is Bangalore based provider of speciality healthcare in India focused on cancer and fertility. It operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. It also operates fertility centres under the ‘Milann’ brand.

Major events and milestones

  • 2005: Entered into the clinical laboratory business through acquisition of Triesta Sciences Inc. and Triesta Sciences (India) Private Limited.
  • 2006: India Development Fund made its first investment of Rs 500 million in the company,
  • 2006: BMORCL became its subsidiary.
  • 2007: HCG Medi-Surge became its subsidiary.
  • 2007: Evolvence made its first investment of Rs 225 million in the company,
  • 2008: NTICPL made its first investment of Rs 400 million in the company.
  • 2009: Amalgamation of Triesta Sciences (India) Private Limited and Triesta Sciences Inc. with the company.
  • 2010: IL&FS Trust Company Limited a/c MPEF, through its scheme India Build Out Fund I and MAT made its first investment of Rs 312 million in the company.
  • 2011: Amalgamation of BMORCL with the company.
  • 2011: PIOF became a Shareholder by purchasing shares from NTICPL.
  • 2013: V-Sciences made its first investment of Rs 600 million in the company.
  • 2013: Entered into the fertility business through acquisition of 50.10% stake in BACC Healthcare.
  • 2014: Demerger of multispecialty division from HCG Medi-Surge and vesting of the same with the company.
  • 2015: HCG Regency became its subsidiary.
  • 2015: Amalgamation of HCG Vijay with the company.

Awards and accreditations

  • 2010: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
  • 2011: The company and its Triesta Reference Laboratory received CAP accreditation valid up to August 25, 2015.
  • 2011: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
  • 2012: HCG cancer centre at Bengaluru received NABH accreditation valid up to May 11, 2018.
  • 2013: The company received the ‘Best Place to Work in Indian Healthcare’ award from People Strong and HOSMAC.
  • 2013: HMS, Ahmedabad received NABH accreditation valid up to June 22, 2016.
  • 2013: Triesta Reference Laboratory received accreditation from the National Accreditation Board for Testing and Caliberation Laboratories for its facilities at HCG Tower, Bengaluru in the field of medical testing valid up to October 13, 2015.
  • 2013: The company was designated an ESMO Designated Centre of Integrated Oncology and Palliative Care.
  • 2013: The company received the ‘Most Innovative Single Specialty Healthcare Entity’ award from VC Circle.
  • 2014: The company received the ‘Golden Peacock Award for Innovation in Management’ from the Institute of Directors.
  • 2014: Its pathology laboratory at HMS received ISO 9001 certification valid up to August 30, 2017.
  • 2015: The company received recognition from the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India for its in-house research and development wing at HCG Tower, Bengaluru.

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+3.95%
1 Week
+14.10%
1 Month
+13.46%
3 Month
+43.54%
6 Month
+67.51%
1 Year
+102.96%
2 Year
+152.69%
5 Year
+25.44%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -0.45 -1.87 -15.10 1.75 0.64 5.38 4.02 -4.18 -26.77
Return on Capital Employed (%) 6.33 4.29 -0.73 6.41 5.60 7.22 7.75 4.50 2.75
Return on Assets (%) -0.20 -0.76 -5.91 0.64 0.25 2.06 1.39 -1.31 -5.87

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 215 292 263 279 426 433 515 477 381
Non Curr. Liab. 148 256 257 279 306 354 394 557 1,232
Curr. Liab. 137 156 149 187 263 366 447 547 576
Minority Int. 8 17 18 25 33 57 64 46 39
Equity & Liab. 508 721 688 770 1,027 1,210 1,421 1,627 2,227
Non Curr. Assets 421 557 578 648 800 966 1,200 1,354 1,923
Curr. Assets 87 164 109 122 227 244 220 273 304
Misc. Exp. not W/O
Total Assets 508 721 688 770 1,027 1,210 1,421 1,627 2,227

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 270 345 450 519 584 700 829 976 1,092
Other Income 4 3 5 5 4 10 19 10 10
Total Income 274 348 455 524 588 710 848 986 1,103
Total Expenditure -227 -293 -413 -443 -499 -595 -716 -853 -923
PBIDT 47 54 42 81 89 115 132 133 179
Interest -24 -29 -32 -34 -38 -23 -42 -70 -138
Depreciation -24 -30 -36 -39 -44 -57 -71 -85 -148
Taxation 0 -1 -5 2 2 -12 -10 3 -6
Exceptional Items -10 -5 -6 11
PAT -1 -5 -42 5 2 23 18 -20 -113

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 18 29 50 60 73 91 98 99 130
Cash Fr. Inv. -39 -100 -58 -80 -204 -210 -282 -238 -101
Cash Fr. Finan. 32 66 23 22 216 89 161 84 -58
Net Change 11 -6 15 2 85 -29 -23 -56 -30
Cash & Cash Eqvt 17 11 25 25 80 51 27 -29 -59

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 23.91 23.91 23.90 23.90 23.90 66.91 66.87 70.71 68.41
Public 76.09 76.09 76.10 76.10 76.10 33.09 33.13 29.29 31.59
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.36 3.47

Announcements View Details

Thu, 29 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate received from our Registrar and Share Transfer Agent - KFin Technologies Private Limited for the period from April 01 2021 to June 30 2021.
Mon, 19 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Sunu Manuel
Designation :- Company Secretary and Compliance Officer
Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
HealthCare Global Enterprises Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 30 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Syngene International Ltd. 25,560.80 637.75 +2.0%
Quess Corp Ltd. 12,813.25 867.20 +6.1%
RattanIndia Enterprises Ltd. 9,247.38 66.90 +4.9%
TeamLease Services Ltd. 7,276.47 4,256.05 +8.3%
SIS Ltd. 7,118.18 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. 7,083.14 270.30 +10.1%
Just Dial Ltd. 6,013.21 964.15 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 60.26 637.75 +2.0%
Quess Corp Ltd. Consolidated 2021-03 221.39 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2021-03 0.00 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2021-06 83.19 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-06 19.27 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2021-06 0.00 270.30 +10.1%
Just Dial Ltd. Consolidated 2021-06 47.23 964.15 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 9.06 637.75 +2.0%
Quess Corp Ltd. Consolidated 2021-03 5.47 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2021-03 108.99 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2021-06 10.73 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-06 3.99 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2021-06 -30.64 270.30 +10.1%
Just Dial Ltd. Consolidated 2021-06 4.77 964.15 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Syngene International Ltd. Consolidated 2021-03 0.28 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 0.51 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.00 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 0.14 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 0.74 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -3.67 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 0.00 964.15 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 16.59 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 -16.80 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.24 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 6.75 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 23.02 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -225.08 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 24.85 964.15 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 15.40 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 -5.79 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.63 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 16.25 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 21.05 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -178.22 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 31.48 964.15 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 2,184.30 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 10,991.48 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 5,200.72 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 9,127.30 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 76.81 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 953.11 964.15 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 404.90 637.75 +2.0%
Quess Corp Ltd. Consolidated 2020-03 -418.05 867.20 +6.1%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.38 66.90 +4.9%
TeamLease Services Ltd. Consolidated 2020-03 37.06 4,256.05 +8.3%
SIS Ltd. Consolidated 2021-03 366.66 485.00 +0.7%
Sun Pharma Advanced Research Company Ltd. Standalone 2020-03 -312.40 270.30 +10.1%
Just Dial Ltd. Consolidated 2020-03 272.31 964.15 -0.2%